Intracellular targeting of Tau-specific single domain antibodies
Tau 特异性单域抗体的细胞内靶向
基本信息
- 批准号:505618676
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Grants
- 财政年份:
- 资助国家:德国
- 起止时间:
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The Tau protein is a common pathophysiological player in cancers and neurodegenerative diseases and, overall, an important therapeutic target. Tau is mainly known as a cytosolic microtubule-associated protein that aggregates into filaments leading to neurodegeneration in pathological conditions referred to as tauopathies. In addition to microtubule dynamics, Tau’s physiological roles also include the protection and reparation of DNA following damage in the nucleus. However, Tau re-expression causes resistance to chemo- or radiotherapy during cancer treatment. The primary goal of the proposal NanoTarget is to develop new antibody-based tools for the intracellular targeting of Tau to modulate the protein’s binding to its partners.Within NanoTarget, the French and German project partners will combine their expertise in biological chemistry, structural biology, biochemistry and molecular physiology to generate cell-permeable Tau-specific nanobodies (Nbs) for their biological evaluation in living cells, including neurons. We will enable applications related to cancer and neurodegeneration, thus requiring delivery of the Nbs at a specific location inside the cell, to reach the core of the pathology. We hypothesize that Tau-specific Nbs could prevent Tau self-association inside neurons in a series of related pathologies called tauopathies, which include Alzheimer’s disease. Furthermore, building upon our ability to engineer Nbs for the compartment-specific cellular delivery, we plan to modulate nuclear Tau function. These cell-permeable Tau-specific Nbs will be chemically modified to monitor their location in cells, thus providing new tools for biological and biomedical research. NanoTarget’s ultimate goal is to provide unprecedented Tau-specific nanobody-based modalities with unmet potential as biological research tools and next-generation biopharmaceuticals. NanoTarget will support our research in the highly competitive field of tauopathies but also extend our original advances in the field of cancer. To date, the potential to reach Tau inside the cells with immunologic approaches has hardly been investigated. The intracellular delivery of functional proteins in living cells, which is essential for NanoTarget, is indeed a challenging task in the molecular life sciences, but it could prove extremely powerful for the development of new drugs. Key factors to be addressed in this context include the stability, cell permeability, and pharmacologic potency of the delivered proteins while maintaining their functional properties. The project’s viability to reach this ambitious goal is supported by the applicants’ proven expertise in protein chemistry and in particular cell-permeable Nb engineering, structural biology, cell biology, their solid track record in Tau research, and their previous successful collaborations.
Tau蛋白是癌症和神经退行性疾病中常见的病理生理学参与者,并且总体上是重要的治疗靶标。Tau主要被称为细胞溶质微管相关蛋白,其聚集成细丝,导致称为Tau病的病理状况中的神经变性。除了微管动力学,Tau的生理作用还包括在细胞核损伤后保护和修复DNA。然而,Tau再表达在癌症治疗期间引起对化疗或放疗的抗性。NanoTarget项目的主要目标是开发新的基于抗体的工具,用于Tau的细胞内靶向,以调节蛋白质与其伴侣的结合。在NanoTarget项目中,法国和德国的项目合作伙伴将联合收割机结合他们在生物化学,结构生物学,生物化学和分子生理学方面的专业知识,以产生细胞可渗透的Tau特异性纳米抗体(Nbs),用于活细胞中的生物学评估,包括神经元。我们将实现与癌症和神经变性相关的应用,从而需要在细胞内的特定位置递送Nbs,以到达病理学的核心。我们假设Tau特异性Nbs可以防止Tau在一系列称为Tau病的相关病理学(包括阿尔茨海默病)中在神经元内的自关联。此外,基于我们工程化Nbs用于隔室特异性细胞递送的能力,我们计划调节核Tau功能。 这些可渗透细胞的Tau特异性Nbs将被化学修饰以监测它们在细胞中的位置,从而为生物学和生物医学研究提供新的工具。NanoTarget的最终目标是提供前所未有的基于Tau特异性纳米抗体的模式,其作为生物研究工具和下一代生物制药的潜力尚未得到满足。NanoTarget将支持我们在竞争激烈的tau蛋白病领域的研究,同时也扩展了我们在癌症领域的原始进展。迄今为止,几乎没有研究过用免疫学方法到达细胞内的Tau的潜力。活细胞中功能蛋白的细胞内递送对于NanoTarget至关重要,在分子生命科学中确实是一项具有挑战性的任务,但它可能对新药的开发非常强大。在这种情况下,要解决的关键因素包括稳定性,细胞渗透性,和药理学效力的交付的蛋白质,同时保持其功能特性。该项目实现这一雄心勃勃目标的可行性得到了申请人在蛋白质化学,特别是细胞渗透性Nb工程,结构生物学,细胞生物学方面的成熟专业知识,他们在Tau研究中的良好记录以及他们之前的成功合作的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Professor Dr. Christian Hackenberger其他文献
Professor Dr. Christian Hackenberger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Professor Dr. Christian Hackenberger', 18)}}的其他基金
Chemoselective Staudinger-induced Michael-additions to antibodies to analyze protein homeostasis in C. elegans
化学选择性施陶丁格诱导的迈克尔添加到抗体中以分析秀丽隐杆线虫的蛋白质稳态
- 批准号:
283309556 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Priority Programmes
New synthetic methods for naturally modified peptides and proteins, their structural evaluation and biological function
天然修饰肽和蛋白质的新合成方法、结构评价和生物学功能
- 批准号:
18634176 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Independent Junior Research Groups
Untersuchungen zur Auswirkung von Protein-Glycosylierungen auf das Faltungsverhalten von Proteinen
蛋白质糖基化对蛋白质折叠行为影响的研究
- 批准号:
5456727 - 财政年份:2005
- 资助金额:
-- - 项目类别:
Research Fellowships
相似国自然基金
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
- 批准号:82373145
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
诱导性多能干细胞rDNA区基因打靶在线粒体视神经病中的治疗研究
- 批准号:81970829
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
- 批准号:81873493
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
以IGF2/IGF1R与SYT/SSX1为靶点治疗滑膜肉瘤的实验研究
- 批准号:81102033
- 批准年份:2011
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于ZFN/phiC31系统的新型基因打靶技术的建立(果蝇)
- 批准号:31171278
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Structural characterization of tau aggregation variability and maturity in isolated cell types of the brain
大脑分离细胞类型中 tau 聚集变异性和成熟度的结构表征
- 批准号:
10721681 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Mechanism of VCP interaction and processing of neurodegenerative tau fibrils
VCP相互作用和神经退行性tau原纤维加工的机制
- 批准号:
10463018 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting MSUT2 with small molecules to ameliorate pathological tau
用小分子靶向 MSUT2 改善病理性 tau
- 批准号:
10735826 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Transcriptomic and Proteomic Analysis of Tau-dependent E/I Imbalance
Tau 依赖性 E/I 失衡的转录组学和蛋白质组学分析
- 批准号:
10789541 - 财政年份:2023
- 资助金额:
-- - 项目类别:
CRISPR gene therapies targeting tau in Alzheimer's disease and tauopathies
针对阿尔茨海默病和 tau 病中 tau 蛋白的 CRISPR 基因疗法
- 批准号:
10752745 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease
靶向 Tau 微管蛋白激酶 1 治疗阿尔茨海默病的治疗评估
- 批准号:
10560906 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Towards Treatment of Alzheimer’s Disease by Targeting Pathogenic Tau and Beta-Amyloid Structures
通过靶向致病性 Tau 和 β-淀粉样蛋白结构来治疗阿尔茨海默病
- 批准号:
10370874 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Mathematical Models of Tau-PET Measures and Cognitive Decline in Alzheimer’s Disease Across the Lifespan
Tau-PET 测量的数学模型和阿尔茨海默病整个生命周期中的认知衰退
- 批准号:
10448899 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Towards Treatment of Alzheimer’s Disease by Targeting Pathogenic Tau and Beta-Amyloid Structures
通过靶向致病性 Tau 和 β-淀粉样蛋白结构来治疗阿尔茨海默病
- 批准号:
10544785 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease
tau 原纤维的脑渗透化学分解剂作为阿尔茨海默氏病的治疗方法
- 批准号:
10384228 - 财政年份:2022
- 资助金额:
-- - 项目类别:














{{item.name}}会员




